Oct. 1, 2005 The clinical outcome for prostate cancer patients who have been treated with hormone therapy and radiation therapy can usually be determined by how rapidly their prostate specific antigen level rises following treatment, according to a report published in the October 1, 2005 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.
Doctors at M.D. Anderson Cancer Center in Houston studied 621 men with prostate cancer treated with hormone and radiation therapy between 1989 and 2003 to determine whether clinical failure after their treatment correlated with the speed at which their post treatment PSA level rose. Clinical failure was defined as cancer recurring in the prostate or spreading to other parts of the body.
Researchers found that measuring how quickly the PSA level doubled was a good indicator of subsequent poor clinical outcomes, including cancer developing in other parts of the body or death related to prostate cancer.
Patients whose PSA level doubled within eight months after treatment failure were more likely to have the cancer return or spread to other parts of the body than patients whose PSA did not double in eight months or less. The estimated five-year rate of clinical failure for patients with a PSA doubling time of more than eight months was only 9.4 percent while 60.4 percent of patients whose PSA doubling time was less than or equal to eight months could expect some type of clinical failure.
"The PSA doubling time is an important indicator of how well a patient will recover from prostate cancer," said Andrew K. Lee, M.D., lead author of the study and a radiation oncologist at M.D. Anderson Cancer Center in Houston. "Although clinical outcomes may be positively affected if the patient receives hormone therapy with radiation therapy, a quickly rising PSA level unfortunately still portends poor results for these patients."
For more information on radiation therapy for prostate cancer, please visit http://www.rtanswers.org.
ASTRO is the largest radiation oncology society in the world, with more than 8,000 members who specialize in treating patients with radiation therapies. As a leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.
Other social bookmarking and sharing tools:
The above story is reprinted from materials provided by American Society for Therapeutic Radiology and Oncology, via EurekAlert!, a service of AAAS.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.